The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.19 annual meeting March 16-18, 2019, in New Orleans. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.


Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables efficient identification of which patients, despite symptoms suggestive of coronary artery disease (CAD), have a low risk of adverse cardiovascular events and can safely avoid invasive testing out to one year. These results from the ADVANCE trial were presented as a late-breaking trial during the American College of Cardiology’s (ACC) 68th Annual Scientific Session, March 16-18 in New Orleans, and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Imaging.

DrChrono Inc. and 3D4Medical have teamed up so practices across the United States can access 3-D interactive modeling and animation videos from within their electronic health record (EHR) to better educate patients.


The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy eating plan, getting more exercise, avoiding tobacco and managing known risk factors are among the key recommendations in the 2019 Primary Prevention of Cardiovascular Disease guideline from the American College of Cardiology (ACC) and the American Heart Association (AHA). Also, it is recommended that aspirin should only rarely be used to help prevent heart attacks and stroke in people without known cardiovascular disease.



As many as one in four patients who undergo cath lab interventions can benefit from a technology that identifies the location of stenoses not resolved by initially performed percutaneous coronary interventions (PCIs) to relieve restricted blood flow.


Researchers from the Stanford University School of Medicine presented preliminary results of the Apple Heart Study, a virtual study with over 400,000 enrolled participants, at the American College of Cardiology (ACC) 68th Annual Scientific Sessions, March 16-18 in New Orleans. The researchers reported that wearable technology can safely identify heart rate irregularities that subsequent testing confirmed to be atrial fibrillation, a leading cause of stroke and hospitalization in the United States.


Virtual reality (VR) and its less immersive kin, augmented reality (AR), are gaining traction in some medical applications. But a new entrant, “mixed reality,” may have the inside track in the interventional suite or operating room.



Machine learning is already having an enormous impact on cardiology, automatically calculating measurements in echocardiograpy. And machine learning, which is part of artificial intelligence (AI), is just getting started.


March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high-voltage cardiac rhythm management (CRM) device families for treatment of patients with cardiac arrhythmias. The six new tachycardia solutions include Rivacor VR-T, Rivacor DR-T, Rivacor HF-T QP, Acticor DX, Acticor CRT-DX Bipolar and Acticor CRT-DX.

The American College of Cardiology’s first annual ACC Quality Summit, held March 13-15 in New Orleans, merges the NCDR (National Cardiovascular Data Registry) Annual Conference and ACC Accreditation Congress for the first time to optimize cardiovascular patient care. The conference brings together cardiovascular thought leaders, administrators, clinicians, clinical quality leaders and data quality experts.

Subscribe Now